IL142150A0 - New crystal modification iii of torasemide - Google Patents

New crystal modification iii of torasemide

Info

Publication number
IL142150A0
IL142150A0 IL14215099A IL14215099A IL142150A0 IL 142150 A0 IL142150 A0 IL 142150A0 IL 14215099 A IL14215099 A IL 14215099A IL 14215099 A IL14215099 A IL 14215099A IL 142150 A0 IL142150 A0 IL 142150A0
Authority
IL
Israel
Prior art keywords
torasemide
new
preparation
crystal modification
new crystal
Prior art date
Application number
IL14215099A
Other languages
English (en)
Original Assignee
Pliva Pharm & Chem Works
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10946825&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL142150(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pliva Pharm & Chem Works filed Critical Pliva Pharm & Chem Works
Publication of IL142150A0 publication Critical patent/IL142150A0/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53Nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/70Sulfur atoms
    • C07D213/71Sulfur atoms to which a second hetero atom is attached
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Liquid Crystal Substances (AREA)
  • Liquid Crystal (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
IL14215099A 1998-10-02 1999-10-01 New crystal modification iii of torasemide IL142150A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HR980532A HRP980532B1 (en) 1998-10-02 1998-10-02 Novel crystalline torasemide modification
PCT/HR1999/000023 WO2000020395A1 (en) 1998-10-02 1999-10-01 New crystal modification iii of torasemide

Publications (1)

Publication Number Publication Date
IL142150A0 true IL142150A0 (en) 2002-03-10

Family

ID=10946825

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14215099A IL142150A0 (en) 1998-10-02 1999-10-01 New crystal modification iii of torasemide

Country Status (32)

Country Link
US (5) US6399637B1 (id)
EP (1) EP1117643B1 (id)
JP (1) JP2002526532A (id)
KR (1) KR100437307B1 (id)
CN (1) CN1125049C (id)
AT (1) ATE286024T1 (id)
AU (1) AU759291B2 (id)
BG (1) BG105485A (id)
BR (1) BR9915018A (id)
CA (1) CA2345789A1 (id)
CZ (1) CZ20011031A3 (id)
DE (2) DE29924789U1 (id)
DK (1) DK1117643T3 (id)
EE (1) EE04341B1 (id)
ES (1) ES2237158T3 (id)
HK (1) HK1040250B (id)
HR (1) HRP980532B1 (id)
HU (1) HUP0104009A3 (id)
ID (1) ID29931A (id)
IL (1) IL142150A0 (id)
NO (1) NO317107B1 (id)
NZ (1) NZ510898A (id)
PL (1) PL346975A1 (id)
PT (1) PT1117643E (id)
RU (1) RU2210569C2 (id)
SI (1) SI1117643T1 (id)
SK (1) SK4232001A3 (id)
TR (1) TR200100909T2 (id)
UA (1) UA72895C2 (id)
WO (1) WO2000020395A1 (id)
YU (1) YU24001A (id)
ZA (1) ZA200102451B (id)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6394707B1 (en) 1997-05-08 2002-05-28 Jack Kennedy Metal Products & Buildings, Inc. Yieldable mine roof support
HRP980532B1 (en) 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
PL354262A1 (en) * 1999-08-11 2003-12-29 Teva Pharmaceutical Industries Ltd.Teva Pharmaceutical Industries Ltd. Torsemide polymorphs
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
HRP20000162B1 (en) 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
HRP20000328A2 (en) * 2000-05-19 2002-02-28 Pliva Farmaceutska Ind Dionik Novel polymorph v of torasemide
IN192178B (id) * 2001-08-03 2004-03-06 Ranbaxy Lab
HRP20020603B1 (en) * 2002-07-19 2008-11-30 Pliva D.D. New process for the preparation of modification i n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide
CA2424644A1 (en) * 2003-04-07 2004-10-07 David John Mckenzie Preparation of torasemide
US20050065183A1 (en) * 2003-07-31 2005-03-24 Indranil Nandi Fexofenadine composition and process for preparing
EP1750862B1 (en) 2004-06-04 2011-01-05 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
JP4406845B2 (ja) * 2007-02-20 2010-02-03 トヨタ自動車株式会社 二次電池電極材の剥離剤及び該剥離剤を用いた二次電池の処理方法
EP2705843A1 (en) * 2012-09-05 2014-03-12 Pharnext Therapeutic approaches for treating epilepsy and related disorders through reduction of epileptogenesis
CN104370805B (zh) * 2013-08-13 2016-09-07 天津汉瑞药业有限公司 托拉塞米化合物
CN106038500A (zh) * 2016-05-26 2016-10-26 南京正科医药股份有限公司 一种托拉塞米片
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法
CN117486789A (zh) * 2023-12-29 2024-02-02 江西中医药大学 一种托拉塞米共晶盐及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4055650A (en) * 1974-04-17 1977-10-25 A. Christiaens Societe Anonyme Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines
GB1477664A (en) * 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
US4473693A (en) 1978-08-04 1984-09-25 Stewart Walter W Aminonaphthalimide dyes for intracellular labelling
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
US6166041A (en) * 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
HRP980532B1 (en) 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US6166045A (en) * 1998-06-02 2000-12-26 Roche Diagnostics Gmbh Torasemide of modification III
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto

Also Published As

Publication number Publication date
US20030055258A2 (en) 2003-03-20
PL346975A1 (en) 2002-03-11
HK1040250A1 (en) 2002-05-31
US20040229919A1 (en) 2004-11-18
CZ20011031A3 (cs) 2001-08-15
HK1040250B (zh) 2004-03-05
EE200100194A (et) 2002-06-17
DE69922977T2 (de) 2005-12-08
HUP0104009A3 (en) 2002-04-29
DE69922977C5 (de) 2008-12-24
BR9915018A (pt) 2001-08-14
SI1117643T1 (en) 2005-06-30
DK1117643T3 (da) 2005-03-29
RU2210569C2 (ru) 2003-08-20
ATE286024T1 (de) 2005-01-15
CA2345789A1 (en) 2000-04-13
CN1321149A (zh) 2001-11-07
US20020147346A1 (en) 2002-10-10
HUP0104009A2 (hu) 2002-02-28
SK4232001A3 (en) 2001-10-08
NO20011633D0 (no) 2001-03-30
ID29931A (id) 2001-10-25
KR100437307B1 (ko) 2004-06-25
BG105485A (en) 2002-01-31
US6833379B2 (en) 2004-12-21
NZ510898A (en) 2002-10-25
TR200100909T2 (tr) 2001-07-23
PT1117643E (pt) 2005-05-31
YU24001A (sh) 2003-02-28
US20060205951A1 (en) 2006-09-14
ES2237158T3 (es) 2005-07-16
HRP980532B1 (en) 2005-06-30
US20070276015A1 (en) 2007-11-29
AU6224099A (en) 2000-04-26
DE69922977D1 (de) 2005-02-03
EP1117643A1 (en) 2001-07-25
AU759291B2 (en) 2003-04-10
NO20011633L (no) 2001-03-30
CN1125049C (zh) 2003-10-22
ZA200102451B (en) 2001-09-28
NO317107B1 (no) 2004-08-09
DE29924789U1 (de) 2005-08-25
KR20010079962A (ko) 2001-08-22
HRP980532A2 (en) 2000-12-31
US6399637B1 (en) 2002-06-04
EE04341B1 (et) 2004-08-16
JP2002526532A (ja) 2002-08-20
WO2000020395A1 (en) 2000-04-13
EP1117643B1 (en) 2004-12-29
UA72895C2 (uk) 2005-05-16

Similar Documents

Publication Publication Date Title
IL142150A0 (en) New crystal modification iii of torasemide
ES8204484A1 (es) Un procedimiento de preparacion de 4,1',6'-tricloro-4,1',6' tridesoxigalactosacarosa
HRP20000092C1 (en) Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole-carboxylic acid and processes for the preparation thereof
CA2429228A1 (en) Improved sucralose composition and process for the crystallization thereof
AU2732395A (en) A cathode material for lithium secondary batteries and a process and a precursor material for the production thereof
WO2001030773A3 (en) Lactonization process
CA2171435A1 (en) Effervescent granulated material and method for its preparation
WO1997013774A3 (fr) Nouveaux derives de la 5-o-desosaminyl 6-o-methyl erythronolide a, leur procede de preparation et leur application a la preparation de produits biologiquement actifs
AU7829787A (en) Naphthalene and indan derivatives
EP0992503A4 (en) METHOD FOR PRODUCING AN ISOOXAZOLIDINDIONED COMPOUND
MY110352A (en) Process for preparing 4-demethoxydaunorubicin.
IE800208L (en) Production of isosorbide-5-nitrate
WO2003055309A8 (en) Method of monitoring/controlling thysanoptera
CA2089193A1 (en) Diacetyl production
EP0922704A4 (en) METHOD FOR THE PRODUCTION AND INTERMEDIATE OF 2- (10,11-DIHYDRO-10-OXODIBENZO [B, F] THIEPIN-2-YL) -PROPIONIC ACID
CA2297112A1 (en) Dicyclanil polymorphs and hydrates and their preparation
CA2252952A1 (en) Substituted aminomethylphenylsulphonylureas, their preparation, and their use as herbicides and plant growth regulators
Zachwieja Single Crystal Growth and Structure Refinement of NaAu sub 2--a New Synthesis Method for Alkali Metal--Gold Compounds
Cotterill et al. The stereochemistry and reactions of some 3, 4-disubstituted chromans
IE830507L (en) Tetrahydropyran derivatives
Maurer et al. Process for producing hydroxylapatite
EP0324221A3 (en) Phenoxyphenyl-substituted tetrazolinones
Duboff et al. Diacetyl production
Wang The effect of TiO sub 2 addition on the thermal behavior of sol-gel derived beta-spodumene powders
Stepien-Damm et al. Crystal structure of TbCoSi